Collegium Pharmaceutical, Inc. COLL Belbuca — Cost
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsGross.
The official record: Collegium Pharmaceutical, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Collegium Pharmaceutical, Inc.'s belbuca — cost.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Collegium Pharmaceutical, Inc.'s belbuca — cost?
- Collegium Pharmaceutical, Inc. (COLL) reported belbuca — cost of $360M in Q1 2026.
- How has Collegium Pharmaceutical, Inc.'s belbuca — cost changed year-over-year?
- Collegium Pharmaceutical, Inc.'s belbuca — cost decreased by 0.0% year-over-year, from $360M to $360M.
- What is the long-term trend for Collegium Pharmaceutical, Inc.'s belbuca — cost?
- Over 3 years (2022 to 2025), Collegium Pharmaceutical, Inc.'s belbuca — cost has grown at a -0.2% compound annual growth rate (CAGR), from $1.45B to $1.44B.
- What does belbuca — cost mean?
- Reflects the total direct costs associated with the production, distribution, and support of the Belbuca product line. Monitoring this helps evaluate the direct cost structure and gross margin efficiency of the specific product segment.